Cancer Research 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 32, 839-846, April 1, 1972]
© 1972 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deckers, P. J.
Right arrow Articles by Pilch, Y. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deckers, P. J.
Right arrow Articles by Pilch, Y. H.

Mediation of Immunity to Tumor-specific Transplantation Antigens by RNA Inhibition of Isograft Growth in Rats

Peter J. Deckers1 and Yosef H. Pilch2

Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20014

Inbred · Fischer 344/N rats were immunized to a benz(a)pyrene-induced Fischer 344/N sarcoma (BP-1R) by the excision of growing tumor transplants. This tumor contained tumor-specific transplantation antigens; spleen cells from rats immunized to this tumor adoptively transferred tumor-specific transplantation immunity to syngeneic, normal recipients. RNA-rich extracts were prepared from the spleens of immunized rats. Normal, nonimmune, syngeneic spleen cells were incubated in vitro with these preparations of "BP-1R-immune" RNA and injected i.v. into Fischer 344/N rats daily for 3 days. The growth of BP-1R isografts in rats inoculated 24 hr after the 3rd injection of these RNA-treated spleen cells was significantly inhibited when compared to recipients of syngeneic spleen cells preincubated with RNA from the spleens of unimmunized Fischer 344/N rats or to untreated controls (no spleen cells). In a similar, but not identical, experiment, BP-1R isografts were inoculated synchronous with the 1st of 3 daily injections of syngeneic spleen cells preincubated with BP-1R-immune RNA. Significant reduction in the incidence of tumor isograft development was noted in recipients of these RNA-treated spleen cells when compared to recipients of untreated Fischer 344/N spleen cells or to untreated controls. Treatment of the active immune RNA preparations with RNase resulted in their complete inactivation.

1 Trainee in Academic Surgery, Boston University School of Medicine, University Hospital, Boston, Mass. 02118.

2 Medical Investigator, Veterans Administration Hospital, Sepulveda, Calif. 91343; Assistant Professor of Surgery and Oncology, Surgical Service, UCLA School of Medicine, Los Angeles, Calif, 90052.

Received 8/12/71. Accepted 1/12/72.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1972 by the American Association for Cancer Research.